Related titles. Carousel Previous Carousel Next. Jump to Page. Search inside document. Classification of CIN based on etiology: 1 Drug-induced: Analgesics phenacetin and acetaminophen [INN paracetamol], either alone or in combination with acetylsalicylic acid and caffeine, nonsteroidal anti- inflammatory drugs , lithium, calcineurin inhibitors cyclosporine [INN ciclosporin], tacrolimus , 5-aminosalicylic acid.
Hendra Tanjung. Kukuh Prasetyo. Guilherme Lima. Jim Weaver. Bella Juni Safira. Cia Zakata. Daniela Paulina Riveros Donoso. Yessica Jimenez. Jefferson Medinaceli Malayao. Shai Edding. Validation of the Finometer Device for Measurement. Aeron Gayadan. Jimmy Zettenberg. Ricca Christyl Sumalpong. Popular in Analgesic Nephropathy. Weir M. Nantel F. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett.
Schnermann J. The macula densa is worth its salt. Cyclooxygenase-2 in the kidney. Noroian G. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. Drug Saf. LeLorier J. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease.
Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Carmichael J. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Dilger K. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.
Schwartz J. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Rossat J. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Patrignani P. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
Expert Opin. Alsalameh S. Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenaseselective inhibitor. Aliment Pharmacol. Whelton A. Effects of celecoxib and naproxen on renal function in the elderly. Swan S. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Cyclooxygenase-2—specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
Brater D. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenaseselective inhibition. Turull A. Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats. Renal failure in cirrhosis. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.
Leehey D. Role of prostaglandins and thromboxane in the control of renal hemodynamics in experimental liver cirrhosis. Ros J. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis.
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Campbell M. Safety of short-term administration of celecoxib in decompensated cirrhosis. Guevara M. Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study. Boyer T. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease.
Zipser R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. Arroyo V. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis.
Relationship to functional renal failure and sodium and water excretion. Mirouze D. Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis.
Quintero E. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Navar L. Paracrine regulation of the renal microcirculation. Juxtaglomerular cell complex in the regulation of renal salt excretion.
Ichihara A. Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. Harding P. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Schricker K. Nitric oxide and prostaglandins are involved in the macula densa control of the renin system.
Cheng H. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. Kammerl M. Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Yang T. Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. Traynor T. Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase Peti-Peterdi J.
Wang J. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Stubbe J. Cyclooxygenase-2 contributes to elevated renin in the early postnatal period in rats. Athirakul K. Kidney Int. Harris C. Renal effects of cyclooxygenase-2 selective inhibitors. Nitric oxide regulates renal cortical cyclooxygenase-2 expression. Renal Physiol. Interactions of the renin-angiotensin system and neuronal nitric oxide synthase in regulation of cyclooxygenase-2 in the macula densa.
Acta Physiol. Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. Hao C. Palmer B. Renal complications associated with use of nonsteroidal anti-inflammatory agents. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.
Harirforoosh S. Effect of nonsteroidal anti-inflammatory drugs with varying extent of COXCOX-1 selectivity on urinary sodium and potassium excretion in the rat. Extent of renal effect of cyclo-oxygenaseselective inhibitors is pharmacokinetic dependent.
Renal effects of COXselective inhibitors. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Kahvecioglu S. Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis.
Nephrology Carlton ; 11 — Curtis S. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Seta F. Renal and cardiovascular characterization of COX-2 knockdown mice.
Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. Zhang M. Cyclooxygenase-2 in rat nephron development.
Khan K. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Morham S. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Dinchuk J. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.
Langenbach R. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cyclooxygenaseselective inhibitors impair glomerulogenesis and renal cortical development. Diamond J. Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis. Prodjosudjadi W. Monocyte chemoattractant protein-1 in normal and diseased human kidneys: an immunohistochemical analysis.
Rovin B. Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Stahl R. Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis.
Grandaliano G. Gamma interferon stimulates monocyte chemotactic protein MCP-1 in human mesangial cells. Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. Satriano J. Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-gamma, tumor necrosis factor-alpha, IgG aggregates, and cAMP in mouse mesangial cells.
Mukaida N. Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor. Jocks T. Prostaglandin E1 reduces the glomerular mRNA expression of monocyte-chemoattractant protein 1 in anti-thymocyte antibody-induced glomerular injury.
Schneider A. Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis.
Rzymkiewicz D. Regulation of prostaglandin endoperoxide synthase gene expression in rat mesangial cells by interleukin-1 beta. Hwang D. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages.
Hirose S. Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis. Blume C. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat.
Tomasoni S. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. Cattell V. Prostaglandin E1 suppresses macrophage infiltration and ameliorates injury in an experimental model of macrophage-dependent glomerulonephritis. Kelley V. Prostaglandin E1 inhibits collagen expression in anti-thymocyte antibody-induced glomerulonephritis: possible role of TGF beta.
Zahner G. Tegeder I. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Perico N. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. Takano T.
Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis. Zoja C. Indomethacin reduces proteinuria in passive Heymann nephritis in rats. Donker A. Treatment of the nephrotic syndrome with indomethacin. Shehadeh I. Indomethacin and the nephrotic syndrome. Okamura M. Suppression of cytokine responses by indomethacin in podocytes: a mechanism through induction of unfolded protein response.
Cyclosporine A suppresses cyclooxygenase-2 expression in the rat kidney. Landewe R. Komers R. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. Cherney D. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats.
Mathiesen E. Elevated urinary prostaglandin excretion and the effect of indomethacin on renal function in incipient diabetic nephropathy. Bakris G. Renal effects of oral prostaglandin suppl. Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes.
Diabetes Care. Nasrallah R. Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in week B6-Ins2 Akita mice. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Retailleau K. Reactive oxygen species and cyclooxygenase 2-derived thromboxane A2 reduce angiotensin II type 2 receptor vasorelaxation in diabetic rat resistance arteries. Cheng X.
Cyclooxygenase-2 inhibitor preserves medullary aquaporin-2 expression and prevents polyuria after ureteral obstruction. COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction.
COX-2 activity transiently contributes to increased water and NaCl excretion in the polyuric phase after release of ureteral obstruction. Chou S. Regional expression of cyclooxygenase isoforms in the rat kidney in complete unilateral ureteral obstruction. Urinary tract obstruction induces transient accumulation of COXderived prostanoids in kidney tissue.
Nielsen S. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Baggaley E. Dehydration-induced increase in aquaporin-2 protein abundance is blocked by nonsteroidal anti-inflammatory drugs. Enhanced intrarenal angiotensin II generation in response to obstruction of the pig ureter. Pimentel J. Sequential changes in renal expression of renin-angiotensin system genes in acute unilateral ureteral obstruction. Yarger W. Obstructive nephropathy in the rat: possible roles for the renin-angiotensin system, prostaglandins, and thromboxanes in postobstructive renal function.
Jensen A. Angiotensin II mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction. Cyclooxygenase 2 inhibition exacerbates AQP2 and pAQP2 downregulation independently of V2 receptor abundance in the postobstructed kidney. Kim S. Indomethacin enhances shuttling of aquaporin-2 despite decreased abundance in rat kidney. Allen H. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus.
Pattaragarn A. Figure 1. Eur Urol. Batlouni M. Arq Bras Cardiol. Wehling M. Non-steroidal anti-inflammatory drugs use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects.
Eur J Clin Pharmacol. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. Rev Bras Anestesiol. Rio de Janeiro; Elsevier: Nonsteroidal anti-inflammatory drugs: prostaglandins, indications, and side effects.
NSAIDs and kidney. J Assoc Physicians India. Effects of nonsteroidal anti-inflammatory meloxicam on stomach, kidney, and liver of rats. Toxicol Ind Health. Eur Rev Med Pharmacol Sci.
Basel: Nonsteroidal Anti-Inflammatory Drugs and the Kidney; pp. Walker C, Biasucci LM. Cardiovascular safety of nonsteroidal anti-inflammatory drugs revisited. Postgrad Med. Kim S, Joo KW. Electrolyte and Acid-base disturbances associated with non-steroidal anti-inflammatory drugs.
Electrolyte Blood Press. Ghane Shahrbaf F, Assadi F. Drug-induced renal disorders. J Renal Inj Prev. Effect of Cyclooxygenase COX -1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney. BMC Vet Res.
Nonsteroidal anti-inflammatory drugs and their effects in the elderly. Aging Health. Am J Ther. Am J Cardiol. Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats. Wiegand TJ. Medscape; Dec, Acute kidney injury.
Khwala A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. Cyclooxygenase in biology and disease. Green GA.
0コメント